ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
MOG antibody-positive patients meeting diagnostic criteria for MS: is it MOGAD with an MS-like phenotype or true MS?
Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- "Low-Positive" MOG-IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Case Report: Overlapping multiple sclerosis and neuropsychiatric systemic lupus erythematosus with positive MOG-IgG: a case initially misdiagnosed as depression.Frontiers in immunology · 2026Article
- AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a recently recognized disorder distinct from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder. The introduction of diagnostic criteria for MOGAD in 2023 marked a significant advance, providing high diagnostic accuracy for typical cases. However, challenges arise when patients test positive for MOG antibodies while also meeting the 2017 McDonald criteria for MS. These cases present a diagnostic dilemma, as they blur the lines between MS and MOGAD, complicating treatment decisions. This review addresses the diagnostic and management challenges faced by these patients, highlighting recent studies that underscore the difficulty in distinguishing between these two diseases and offering insights into how to approach these ambiguous cases.
Indexed as
Identifiers
40266423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.